Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing

Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing

AdvertisementSKIP ADVERTISEMENTConcerns that well-funded Chinese companies will swoop in to grab new ideas for their own drug development are shaping an industry unaccustomed to such secrecy.Fears that Chinese companies will seize on biotech discoveries in the U.S. and quickly beat them to market with their own inventions or slightly altered dupes have prompted American companies to keep their discoveries secret.Credit...Florence Lo/ReutersGina KolataGina Kolata spoke to 18 biotech executives and investors and read testimonies and reports to Congress on the China challenge.Nov. 17, 2026, 5:01 a.m. ETIt used to be that companies and scientists with ideas for new drugs couldn’t wait to announce their discoveries at meetings, in preprints and on their websites.That is changing.Researchers at the biotechnology firm Alnylam Pharmaceuticals have an unwritten policy: Do not reveal early-stage studies or discuss unpublished data, according to its founding chief executive, Dr. Christoph Westphal.Jacob Becraft of Strand Therapeutics delays filing for patents to keep his company’s discoveries secret. And he is careful about disclosing his company’s intellectual property and confidential material, even to investors.Alexis Borisy, a co-founder of Curie.Bio, which helps early-stage biotechs, says he tells scientists to “go dark” — don’t publish, don’t present posters at meetings, don’t even go to meetings.The reason for this guarded stance? Fears that Chinese companies will seize on the biotechs’ discoveries and quickly beat them to market with the U.S. firms’ own inventions or with slightly altered versions that dilute market exclusivity.“This is the world we’re in now,” Mr. Borisy said. Meetings are where scientists discuss new ideas. Publication is the lifeblood of science. But now, being too open too soon has become too risky, he and others said.The concern is not only the risk of a significant economic hit if the United States cedes most of its biotech industry to China. It’s also a fear of direct effects on patients — the possibility that China might use access to drugs as a cudgel, experts said.China has used its control of other resources that way, like its meting out of rare-earth minerals, a tactic used in trade wars with the United States. If China controls access to a valuable drug, like a cancer treatment for instance, it could use it for political leverage, warned the National Security Commission on Emerging Biotechnology, an advisory group, in a report to Congress.ImageAlnylam Pharmaceuticals in Cambridge, Mass., has an unwritten policy: Do not reveal early stage studies nor discuss unpublished data.Credit...Adam Glanzman/BloombergThe Chinese Communist Party heavily subsidizes its biotech industry and says biotech is its highest priority, on par with artificial intelligence. Its five-year plan calls for China to make at least 25 percent of the world’s “first in class innovative medicines” over the next five years.“With the trajectory they are on, I think they are being conservative,” said John Crowley, president and chief executive of BIO, an advocacy group. With lavish support, Chinese companies have been discovering more and more promising drugs. Mr. Crowley added that today about 30 to 35 percent of innovative medicines under development are of Chinese origin.The United States, meanwhile, has a funding problem, said Cyriac Roeding, an investor. Small biotech companies depend on investors, which leaves them at the mercy of boom-and-bust cycles during the 10 to 12 years it takes to bring a drug to market.The National Security Commission on Emerging Biotechnology made that same point in its report, writing that the nation needs a “‘private-public’ partnership for biotechnology driven by industry in collaboration with government.”Multiple biotech executives, investors and those who study the industry, say their fears — that China is not playing fair, and that American biotech will lag in the future — are well-founded.A recent paper in JAMA outlined China’s rise: In 2015, 48 percent of early-stage drug development was in the United States and 8 percent was in China. In 2024, 37 percent was in the United States and 32 percent was in China.“My prediction is they will leapfrog us in biotechnology in the not too distant future,” said Dr. Steven Paul, a partner in the health care venture firm Third Rock Ventures.ImageZhang Guoqing, the Chinese vice premier, on a visit to a biotechnology firm in Inner Mongolia this year. The Chinese Communist Party heavily subsidizes its biotech industry and says biotech is its highest priority.Credit...Ma Jinrui/Xinhua, via Getty Images‘Disingenuous Competition’Mr. Borisy cautioned that “disingenuous competition” was prompting American biotechs’ tactic of “going dark”: In one form of it, he said, Chinese investigators use A.I. agents that scour presentations at every scientific conference and rifle through every patent.“The moment anything is out there, it is tracked,” Mr. Borisy said, adding that if there is a new idea, companies in China will seize on it. Many will get nowhere but, he said, if even a couple of these companies succeed, they can get a clinical trial going much faster than the U.S. inventors can.Chinese companies, Mr. Crowley noted, can complete clinical trials “three times quicker than we can and at half the cost.”Dr. Becraft said he and others had grown leery of representatives of Chinese companies at meetings who say they are investors and dangle promises of millions of dollars. These “investors,” he said, have sometimes turned out to be scouting for a company’s discoveries and do not in fact have money to offer. “I’ve stopped talking to them,” Dr. Becraft said.At other times, Chinese competitors employ a technique that biotech firms call fast-follower/design-around: A U.S. company invents a drug and patents it; a Chinese company changes its design slightly to get around the U.S. patent.ImageRevolution Medicines drug for pancreatic cancer, daraxonrasib.Credit...Kim Raff for The New York TimesThat is what Revolution Medicines alleges happened to it. Its scientists worked for years to develop a drug for people with a gene mutation that drives nearly all pancreatic cancers. They patented the stunningly effective design, but then, seemingly out of nowhere, Chinese scientists licensed a nearly identical drug to a U.S.-based company, Erasca. Revolution Medicines said its trade secrets were “misappropriated.” Erasca denied the allegations.Lisa Roessler says her company, Amyris, has been plagued by what she describes as outright data theft. Amyris engineers specialized yeast whose products can be used, for example, in vaccines and cosmetics. Its 15 commercial products took years and millions of dollars to develop. But recently, at trade shows, Chinese companies have been advertising the same products — presented with the same data, including the same number of people in clinical trials, the same results and other such impossibilities.“One of the things we’ve seen is descriptions of our products, not just word for word but the data in brochures is literally our data, in the same format,” Ms. Roessler said.China has denied previous claims that it steals trade secrets. “The Chinese government will not, in whatever form, engage in commercial theft or encourage or support such attempts by anyone,” said President Xi Jinping of China in a public speech in Seattle in 2015.Fear of reprisalStories of research appropriation abound, although few companies want to talk publicly about the details of what happened to them.There’s a reason for that, said Melissa Roberts Chapman, president of KC Biohub. “If you were to make an allegation and later want to bring a drug to market in China, you might have trouble.”Ms. Roessler added that most American companies depend on China to manufacture their drugs and conduct early-stage clinical trials. Those who criticize China can be, and have been, punished by denial of access.Dr. Becraft said that after he began speaking out there was a five- to 10-fold increase in cyberattacks on his company’s computers and his private accounts. A U.S. government official told him it would be best if he did not travel to China.ImageA San Diego facility for the biotech firm Erasca, a competitor to Revolution Medicines.Credit...JHVEPhoto, via AlamyThe industrywide fear of reprisal was particularly apparent in May, when the U.S. International Trade Commission held a hearing in Washington on China’s threat to biotechs. The group had invited 297 individuals and groups to testify. But, Ms. Chapman said, when it came to the hearing, “only eight were in the room.”Not everyone thinks the dangers are as real as they’re made out to be, however.Peter Kolchinsky, an investor and managing partner of RA Capital Management, says that misguided fears about China are actually driving flawed policy proposals. “China hawks,” as he called them, often cite the rare-earth example, saying that just as China cornered the rare-earth market and used it for political advantage, it could do the same thing with drugs.He disagreed. “Drugs are not commodities,” said Mr. Kolchinsky, whose more than 200 companies are mostly in the United States. “The equivalent of the rare-earth situation would be if the U.S. relied on China to manufacture all drugs.”But, he added, that is not happening, and, with careful planning, it need not happen for individual drugs.Mr. Kolchinsky said the solution to the China threat was not to restrict collaborations with or investment in Chinese firms. That can harm rather than help American companies, he said, because U. S. investors and companies will not know what’s going on in China. That will make it hard to know when a U.S. company’s product is the best.What the ultimate path forward may be is unclear, however, when every avenue to presenting or sharing ideas could lead to theft. And few think legal actions will solve the bigger problem.Today’s situation “is not an accident,” said Caitlin Frazer, executive director of the National Security Commission on Emerging Biotechnology. Instead, it is the product of 20 or 25 years of a deliberate strategy by the Chinese government, with a doubling down on the effort in the latest update to the Chinese government’s five-year plan.Last year, the commission published a report on how to save the nation’s biotech industry. It made 49 recommendations and said the United States needed to provide incentives for research, speed clinical trials and reduce investment risk.Mr. Crowley of Bio said it was not too late for U.S. biotech. “Unlike in chips, where we totally lost it, we still have the lead in biotech,” he said.But, he said, there is no time to waste: “We need to be sure we don’t wake up and see biotech wither.”Gina Kolata reports on diseases and treatments, how treatments are discovered and tested, and how they affect people.Related ContentAdvertisementSKIP ADVERTISEMENT

Original Source

Read the full article at Nytimes →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.